Pulmatrix
99 Hayden Avenue
Suite 390
Lexington
Massachusetts
02421
United States
Tel: 781-357-2333
Fax: 781-357-2399
Website: http://www.pulmatrix.com/
Email: info@pulmatrix.com
190 articles about Pulmatrix
-
Pulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternatives
1/8/2024
Pulmatrix today announced that it has entered into a further amendment to its agreement with Cipla for the development of PUR1900 in the treatment of Allergic Bronchopulmonary Aspergillosis (ABPA).
-
Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update
11/9/2023
Pulmatrix, Inc. announced third quarter financial results for 2023 and provided a corporate update on its development programs.
-
Pulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine
9/19/2023
Pulmatrix, Inc. today announced the U.S. Food and Drug Administration ("FDA") has accepted the PUR3100 investigational new drug ("IND") application and the Company has received a study may proceed letter for a Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single Event Study to Evaluate the Safety, Tolerability, and Efficacy of PUR3100 (Dihydroergotamine Mesylate Inhalation Powder) in the Acute Treatment of Migraine.
-
Pulmatrix Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole
8/23/2023
Pulmatrix is currently enrolling patients in a Phase 2 study of PUR1900 in adults with ABPA and Asthma.
-
Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Update
8/10/2023
Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and central nervous system disease using its patented iSPERSE™ technology, today announced second quarter financial results for 2023 and provided a corporate update on its development programs.
-
Pulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine
7/11/2023
Pulmatrix, Inc. today announced the submission of an investigational new drug ("IND") application to the United States Food and Drug for PUR3100, an orally inhaled dry powder formulation of dihydroergotamine ("DHE"), under development to treat acute migraine.
-
Pulmatrix Presents PUR3100 Phase 1 Data at the 65th Annual Meeting of the American Headache Society
6/15/2023
Pulmatrix, Inc. announced it will present data at the American Headache Society 65th Annual Meeting, being held from June 15th through 18th both virtually and in-person at the J.W. Marriott in Austin, Texas.
-
Pulmatrix Selected to Present at the Annual Biotechnology Innovation Organization (BIO) International Convention
5/24/2023
Pulmatrix, Inc. today announced that management will present at the annual Biotechnology Innovation Organization (BIO) International Convention, to be held in-person in Boston, MA, June 5 - 8, 2023.
-
Pulmatrix Announces First Quarter 2023 Financial Results and Provides Corporate Update
5/12/2023
Pulmatrix, Inc. (NASDAQ: PULM) today announced first quarter financial results for 2023 and provided a corporate update on its development programs.
-
Pulmatrix Announces Year-End and Q4 Financial 2022 Results and Provides Corporate Update
3/30/2023
Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and central nervous system disease using its patented iSPERSE™ technology, today announced fourth quarter and year-end financial results for 2022 and provided a corporate update on its development programs.
-
Pulmatrix Announces First Patient Dosed in Phase 2b Study of PUR1900 for Treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) in Subjects with Asthma
2/6/2023
Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using its patented iSPERSE™ technology, today announced the first patient dosed in a Phase 2b trial evaluating safety and efficacy of PUR1900 in subjects with Allergic Bronchopulmonary Aspergillosis (ABPA) and asthma.
-
Pulmatrix to Host Key Opinion Leader Webinar "PUR3100 for the Treatment of Acute Migraine: Unlocking the Potential of DHE Treatment"
1/25/2023
Pulmatrix, Inc. (NASDAQ: PULM) today announced it will host a virtual key opinion leader (KOL) event, "PUR3100 for the Treatment of Acute Migraine: Unlocking Potential of DHE Treatment", featuring Stewart J. Tepper, MD, from the Geisel School of Medicine at Dartmouth College.
-
Pulmatrix to Present Data on PUR1800 at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology
1/23/2023
Pulmatrix, Inc. today announced the acceptance of an abstract for presentation at the American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting.
-
Pulmatrix Announces Positive Top Line Results from a Phase 1 Study with PUR3100, a Novel Orally Inhaled Dihydroergotamine (DHE), for Acute Migraine
1/4/2023
Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using its patented iSPERSE™ technology, today announced successful completion of a Phase 1 trial evaluating safety and pharmacokinetics of PUR3100 in healthy volunteers.
-
Pulmatrix Announces Third Quarter 2022 Financial Results and Provides Corporate Update
11/10/2022
Pulmatrix, Inc. today announced third quarter financial results for 2022 and provided a corporate update related to its development programs.
-
Pulmatrix Announces Patient Dosing Completed for its Novel Inhaled Therapy PUR3100 for Acute Migraine
9/26/2022
Pulmatrix, Inc. today announced that all subjects have completed dosing in a Phase 1 trial evaluating PUR3100, a novel orally inhaled formulation of dihydroergotamine (DHE) in healthy volunteers.
-
Pulmatrix Announces Second Quarter 2022 Financial Results and Provides Corporate Update
8/8/2022
Pulmatrix, Inc. today announced second quarter financial results for 2022 and provided a corporate update related to its development programs.
-
Pulmatrix Announces First Subject Dosed in Phase 1 Study of PUR3100 for Acute Migraine
7/12/2022
New inhaled formulation of dihydroergotamine (DHE) intended for acute migraine therapy begins clinical development with Phase 1 study.
-
Pulmatrix Announces First Quarter 2022 Financial Results and Provides Corporate Update
5/12/2022
Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today announced first quarter financial results for 2022 and provided a corporate update.
-
Pulmatrix Announces Year-End and Q4 Financial 2021 Results and Provides Corporate Update
3/29/2022
Pulmatrix, Inc. announced fourth quarter and year-end financial results for 2021 and provided a corporate update.